Hammes Stephen R, Davis Paul J
Division of Endocrinology, Department of Medicine, University of Rochester School of Medicine, Rochester, NY, USA.
Department of Medicine, Albany Medical College, Albany, NY, USA; Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA.
Best Pract Res Clin Endocrinol Metab. 2015 Aug;29(4):581-93. doi: 10.1016/j.beem.2015.04.001. Epub 2015 Apr 22.
The genomic actions of thyroid hormone and steroids depend upon primary interactions of the hormones with their specific nuclear receptor proteins. Formation of nuclear co-activator or co-repressor complexes involving the liganded receptors subsequently result in transcriptional events-either activation or suppression-at genes that are specific targets of thyroid hormone or steroids. Nongenomic actions of thyroid hormone and steroids are in contrast initiated at binding sites on the plasma membrane or in cytoplasm or organelles and do not primarily require formation of intranuclear receptor protein-hormone complexes. Importantly, hormonal actions that begin nongenomically outside the nucleus often culminate in changes in nuclear transcriptional events that are regulated by both traditional intranuclear receptors as well as other nuclear transcription factors. In the case of thyroid hormone, the extranuclear receptor can be the classical "nuclear" thyroid receptor (TR), a TR isoform, or integrin αvβ3. In the case of steroid hormones, the membrane receptor is usually, but not always, the classical "nuclear" steroid receptor. This concept defines the paradigm of overlapping nongenomic and genomic hormone mechanisms of action. Here we review some examples of how extranuclear signaling by thyroid hormone and by estrogens and androgens modulates intranuclear hormone signaling to regulate a number of vital biological processes both in normal physiology and in cancer progression. We also point out that nongenomic actions of thyroid hormone may mimic effects of estrogen in certain tumors.
甲状腺激素和类固醇的基因组作用取决于这些激素与其特定核受体蛋白的初始相互作用。涉及配体化受体的核共激活因子或共抑制因子复合物的形成随后会导致转录事件——激活或抑制——发生在作为甲状腺激素或类固醇特定靶标的基因上。相比之下,甲状腺激素和类固醇的非基因组作用始于质膜、细胞质或细胞器上的结合位点,并且主要不需要形成核内受体蛋白 - 激素复合物。重要的是,在细胞核外开始的非基因组激素作用通常最终会导致核转录事件的变化,这些变化由传统的核内受体以及其他核转录因子共同调节。就甲状腺激素而言,核外受体可以是经典的“核”甲状腺受体(TR)、TR 异构体或整合素αvβ3。就类固醇激素而言,膜受体通常但不总是经典的“核”类固醇受体。这一概念定义了非基因组和基因组激素作用机制重叠的范式。在此我们回顾一些例子,说明甲状腺激素以及雌激素和雄激素的核外信号传导如何调节核内激素信号传导,从而在正常生理学和癌症进展过程中调节一些重要的生物学过程。我们还指出,甲状腺激素的非基因组作用在某些肿瘤中可能模拟雌激素的作用。